Bulevirtide
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Modeling hepatitis D virus kinetics during bulevirtide monotherapy: challenges and solutions
Announce Type: replace Abstract: The entry inhibitor Bulevirtide (BLV) was recently approved in Europe for treatment of chronic hepatitis D virus (HDV) infection, which is considered the most severe viral hepatitis infection. Theory indicates that models that account for free virus and infected cells, but do not include target cell dynamics (historically called the two-equation model) are limited to predicting a monophasic viral decline for antiviral agents that act only to block viral...